依达拉奉(MCI-186)治疗急性脑梗死的临床观察  

Clinical Evaluati of Edaravone for Acute Cerebral Infarction

作　　者：王丹[1] 朱浩佳[1] 梁焯辉[1] 

机构地区：[1]广东省江门市人民医院神经内科,江门529051

出　　处：《中国临床医学》2005年第2期340-341,共2页Chinese Journal of Clinical Medicine

摘　　要：目的:观察依达拉奉(MCI 186)治疗急性脑梗死(ACI)的临床疗效。方法:选择发病72 h内的ACI患者72 例,随机分为依达拉奉治疗组33例和对照组39例。治疗组应用依达拉奉静脉给药,剂量为30mg,2次/d,共计14d,余治疗与对照组相同。治疗前后对患者进行改良爱丁堡斯堪的那维亚量表(SSS)及日常生活能力(ADL)的测定。结果:治疗14 d后,治疗组SSS由治疗前的(20.83±11.36)下降到治疗后的(7.83±8.72),具有显著差异(p<0.01);对照组SSS由治疗前的(21.56±10.27)下降到治疗后的(12.56±7.36),具有显著差异(p<0.05);两组治疗后相比具有显著差异(p<0.05)。治疗组ADL由治疗前的(35.36±23.45)上升到治疗后的(68.46±28.43),具有显著差异,(p<0.01);对照组ADL由治疗前的(33.53±20.70)上升到治疗后的(52.72±24.81),具有显著差异,(p<0.01);两组治疗后相比具有显著差异(p<0.05)。治疗组无不良反应。结论:依达拉奉治疗急性脑梗死安全有效。Objective:To investigate the effects of Edaravone on acute cerebral infarction. Methods: 72 cases of acute cerebral infarction (ACI), enrolled within 72h of onset, were randomly divided into the Edaravone group (33 cases) and control group (39 cases). Edaravone was infused at a dose of 30mg, twice a day, for 14 days. The therapies of the control group were similar to those of Edaravone group except for Edaravone. We assessed Scandinavian Stroke Scale (SSS) and activities of daily living (ADL) before and after treatment. Results: After 14 th day treatment, there was a significant difference of SSS score between pre-cure Edaravone group ( 20.83± 11.36)and post-cure Edaravone group( 7.83± 8.72)(p< 0.01), there was a significant difference of SSS score between pre-cure control group ( 21.56± 10.27)and post-cure control group( 12.56± 7.36)(p< 0.05),the SSS score of post-cure Edaravone group was significantly lower than that of control group(p< 0.05). There was a significant difference of ADL score between pre-cure Edaravone group (35.36±23.45)and post-cure Edaravone group( 68.46± 28.43)(p< 0.01), there was a significant difference of ADL score between pre-cure control group( 33.53± 20.70)and post-cure control group( 52.72± 24.81)(p< 0.01),the ADL score of post-cure Edaravone group was significantly higher than that of control group(p< 0.05). There was no distinct adverse reaction in Edaravone group. Conclusion:Edaravone was an effective and safe medicine in the treatment of acute cerebral infarction.

关 键 词：急性脑梗死 依达拉奉 临床观察 日常生活能力 治疗后 治疗组 无不良反应 对照组 临床疗效 静脉给药 治疗前后 SSS ADL ACI 72h 患者 下降 相比 上升 

分 类 号：R743.33[医药卫生—神经病学与精神病学] R971[医药卫生—临床医学]